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Summary The ability of a range of 2-nitroimidazoles with similar electron affinities but widely differing
partition coefficients (P) to enhance the cytotoxicity of cyclophosphamide (CY) in mouse tumour and normal
tissues was investigated. In a preliminary study large single doses of benznidazole (BENZ), misonidazole
(MISO), desmethylmisonidazole (DMM), and SR-2508 were found to give similar enhancement of the RIF-I
and SCC VII/St tumours. SR-2555 was less effective. A direct comparison was made between MISO and
SR-2508 using prolonged, low-level drug exposures, achieved by multiple injections. The enhancement of CY
cytotoxicity achieved in the two tumour systems (RIF-l and SCC VII/St) was found to be similar for a given
blood sensitizer concentration. In the normal tissue assays (white blood cell count, bone marrow CFU-S and
testis spermatogonia) neither MISO nor SR-2508 produced significant enhancement of CY cytotoxicity, so
that the therapeutic gains achieved at a given blood concentration of sensitizer were similar for SR-2508 and
MISO. The main advantage of SR-2508, however, will probably lie in its lower toxicity, permitting higher
blood levels to be achieved. However, the slope of the dose response curves are rather shallow so we would
not predict a dramatically increased benefit.
The combination of nitroimidazole radiosensitizers
with chemotherapeutic agents has been the subject
of much recent research. In general, there is
agreement that the largest enhancements are seen
when nitroimidazoles, particularly misonidazole
(MISO), are combined with compounds having
bifunctional alkylating activity. There is evidence
that at least part of this effect for some of these
alkylating agents can result from altered pharmaco-
kinetics of the agent (Hinchcliffe et al., 1983; Lee &
Workman, 1983), but it seems likely that other
mechanisms exist to explain the relative sparing of
normal tissues reported in many studies. In
particular, the hypoxia-mediated enhancement of
the formation of DNA interstrand crosslinks seen
in vitro (Taylor et al., 1983) is a particularly
attractive explanation of this tumour selectivity.
It has been shown that tumour sensitization to
nitrosoureas by nitroimidazoles is not directly
related to their efficiency as radiosensitizers.
Sensitization to the nitrosourea CCNU has been
investigated in some detail (Siemann, 1982;
Workman & Twentyman, 1982a,b; Hirst et al.,
1983), and it is clear that the chemosensitizing
ability of a series of nitroimidazoles of similar
electron-affinity administered as large single doses
varies with octanol:water partition coefficient (P).
Compounds with P values in the range 2 to 10
show the greatest efficiency. In our own recent
study (Hirst et al., 1983) we have observed a broadly
similar relationship when the nitroimidazoles
were given as multiple small injections to maintain
a low plasma concentration for several hours,
similar to the longer half-life that might be ex-
pectedin man. However, itremains uncertainwhether
MISO, at clinically relevant exposure levels,
will always provide a therapeutic gain when
combined with commonly used alkylating agents.
Our own investigations (Brown & Hirst, 1982; Hirst
et al., 1982) have shown definite enhancement of
L-PAM and cyclophosphamide (CY) cytotoxicity to
tumours at these MISO exposures. Enhancement of
CCNU cytotoxicity was very variable between
different tumour lines and, where it occurred, was
generally modest. With each of these three chemo-
therapeutic agents no significant enhancement of
dose-limiting normal tissue toxicity was produced
by MISO at these clinical dose levels.
The present study concerns the ability of a range
of 2-nitroimidazoles with widely differing partition
coefficients but very similar electron-affinities to
enhance CY cytotoxicity in mouse tumour and
normal tissue systems. Our principal objective was
to study the effects obtained with prolonged
exposure to low levels of the nitroimidazoles and
in particular to evaluate in detail the relative merits
for clinical use of MISO and the more hydrophilic
but less toxic sensitizer, SR-2508. We have shown
that the enhancement of CY cytotoxicity is only
weakly, or not at all, dependent on P and that SR-
2508 may be a sensitizer superior to MISO for
clinical use, if only because higher doses can be
tolerated.
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Materials and methods
Animal and tumour systems
The two tumour systems employed in these
experiments have been used extensively in our
laboratory and have been described in detail in
previous publications. The non-immunogenic RIF-1
sarcoma (Twentyman et al., 1980; Brown et al.,
1980) in its syngeneic host, the C3H/Km mouse is
sensitive to CY. Its response was assayed either by
regrowth delay of tumours implanted i.m. in the leg
(Law et al., 1981) or by cell survival in vitro of
tumours treated in vivo (Law et al., 1981). This
assay was carried out in tumours implanted both
i.m. in the leg or s.c. in the flank. Tumours were
excised 24h after treatment with CY in every
experiment. The SCC VII/St carcinoma is also non-
immunogenic in the C3H/Km mouse but is more
resistant to CY than is the RIF-1. Details of its
derivation have been described previously (Hirst et
al., 1983). The response of this tumour was assayed
by in vivo-in vitro assay of tumours implanted s.c.
in the flank (Hirst et al., 1983). With both tumour
systems, cell survival was determined from 3-4
pooled tumours/group. Cells from each of these
groups were then plated in petri dishes as
previously described (Law et al., 1981; Hirst &
Brown, 1982) using two cell dilutions per
experimental group. Regrowth of the RIF-1
tumours was measured in 5-7 animals/group.
Normal tissue studies
Three normal tissue end points were used to assess
the effects of the various drug treatments. Survival
of bone marrow stem cells was determined using
the spleen colony assay (Till & McCullough, 1961).
The procedures used were similar to those used in a
prior study (Law et al., 1981). Bone marrow cells
were flushed with cold Hank's solution from the
femurs of treated animals and an appropriate
number of cells were injected via a tail vein into 6
preirradiated (7.5Gy whole body) recipients of the
same strain and sex. A count of spleen colonies 8
days later allowed the relative cell survival of the
different groups to be measured. An advantage of
this end point is that it can be determined in the
same animals as are used to measure tumour
response. However, we considered it inadequate to
use as the only normal tissue in the present study as
the error limits obtained with this assay do not
permit small changes to be distinguished at the
relatively high levels of cell survival seeni in these
experiments. Also, bone marrow stem cells may not
be the dose limiting cell population with CY, so
white blood cell counts were also made 4 days after
drug treatment. This interval corresponds with the
nadir in the cell count after CY treatment, as
determined previously (Law et al., 1981). The same
procedures were used in the present study to obtain
values for total and differential white cell counts.
Six animals were used for each treatment group.
The third normal tissue end-point measured the
response of differentiated spermatogonia, by
counting the number of sperm heads in testis
homogenates at 29 days after drug treatment as
described originally by Lu et al. (1974). Details of
this technique have been given in a prior
publication (Hirst et al., 1983). Data obtained with
this assay are highly repoducible, so only three
animals were used per datum point.
Drug injections and blood drug levels
The first series of experiments in this study was
carried out using large single doses of nitro-
imidazoles in combination with single doses of
CY. Details of the drugs and how they were
administered are given in Table I. SR-2508 and SR-
2555 were given i.v. because their uptake from the
peritoneal cavity is slow. Benznidazole (BENZ) has
a low solubility in saline and so peanut oil had to
be used as a solvent for administering high doses of
this drug. Large single doses of the nitroimidazoles
were given 30min before the CY, as previous
experience had shown this to be the most effective
interval for MISO and SR-2508 (Law et al., 1981).
In the experiments with multiple injections of
nitroimidazoles, blood samples were taken to
monitor the levels achieved. Multiple injection
experiments were carried out only with SR-2508
and MISO. The procedure used was the same as
that described previously (Brown & Hirst, 1982)
except that the doses were varied over a wide range
(mean blood levels ranging from 15jugml-
600jugml-' were maintained for 7h). CY injections
were given 4h after the first injection of sensitizers.
Blood samples were taken from the tail 15min after
each injection of sensitizer and the level of drug
was determined using reverse-phase high-
performance liquid chromatography (Brown &
Hirst, 1982).
Results
The experiments in this study are presented in two
parts. First, a preliminary series in which the ability
of large single doses of several 2-nitroimidazoles
with different partition coefficients to enhance the
cytotoxicity of CY in the RIF-1 and SCC VII/St
tumours was assessed. Second, a more detailed
series where the two most promising compounds,
MISO and SR-2508, were administered over a wide
dose range.
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Table I Sensitizer injection schedules
Large single doses
Sensitizer Solvent Route Dose (mmolkg-1) Injection volume (mlg-1)
SR-2555 Saline i.v. 2.0 0.01
SR-2508 Saline i.v. 2.0 and 3.75 0.01
DMM Saline i.p. 2.0 0.03
MISO Saline i.p. 2.0 and 3.75 0.03
BENZ Peanut oil i.p. 2.0 0.01
Multiple injections
Treatment Injections Total volume
Sensitizera designation given (mmolkg-1) injected (mlg-1)
SR-2508 or MISO x/4 I x0.15+14x0.038 0.15
MISO x/2 1 x0.30+14x0.075 0.15
SR-2508 or MISO x 1 x0.60+ 14 x0.15 0.15
MISO 2x lx 1.2 +14x0.30 0.15
SR-2508 4x 1x2.4 +14x0.60 0.15
SR-2508 8x 1x 4.8 + 14 x 1.20 0.15
'All injected i.p. in saline.
Table II The influence of partition coefficient (P) on enhancement of CY
cytotoxicity
Days to reach 4x
treatment vol. Survivingfraction (%)
(±s.e.) (±s.e.)
Treatment
sensitizer
(2mmolkg-1) (P) RIF-J RIF-J SCC VII/St
Saline +Saline - 4.5+0.3 100 100
Saline +CY(50)a 9.1+0.4 9.40+ 1.6 23+3.0
Saline +CY(50) 9.3 +0.6
SR-2555 +CY(50) 0.026 9.7+0.7 1.90+0.05
SR-2508 +CY(50) 0.046 11.8+0.9 0.95+0.06 5.9+0.5
DMM +CY(50) 0.13 13.0+0.5
MISO +CY(50) 0.43 17.0+1.5 0.95+0.64 3.4+1.2
BENZ +CY(50) 8.5 12.8+0.8 0.53+0.10 2.8+0.3
Saline +Saline 4.7+0.4
Saline +CY(I00)a 16.4+0.6
SR-2555 +CY(100) 0.026 17.8+1.0
SR-2508 +CY(100) 0.046 22.6+1.1
DMM +CY(100) 0.13 19.8+0.5
MISO +CY(100) 0.43 20.3+ 1.2
BENZ +CY(100) 8.5 18.3+0.7
aDose of CY in mgkg- given 30min after sensitizer injection.36 D.G. HIRST et al.
two different doses of CY of single doses of
2mmolkg-' of several 2-nitroimidazoles. All the
compounds enhanced CY cytotoxicity to some
extent, but the effect of SR-2555 was negligible.
MISO, Desmethylmisonidazole (DMM), BENZ,
and SR-2508 showed similar enhancement though,
with the exception of SR-2508, they had less effect
at the higher dose of CY, a trend similar to that
observed previously for MISO (Law et al., 1981).
The ability of several of the nitroimidazoles to
enhance CY cytotoxicity are also compared in the
RIF-I and SCC VII/St tumours using the in vivo-in
vitro assay system. In each of the tumours, all the
compounds tested enhanced cell killing by CY.
These preliminary experiments showed clearly
that the range of 2-nitroimidazoles (with the
exception of the very hydrophilic SR-2555) did not
differ greatly in their ability to enhance CY cyto-
toxicity and that MISO was probably as good as if
not better than any other compound, at least under
the conditions of administration used in these
experiments. However, since a compound with
lower toxicity could prove to be of greater clinical
value, a detailed comparison of the enhancing
capability of MISO with that of the more hydro-
philic and less toxic SR-2508 was made using single
and multiple doses ofthe two drugs.
Large andsingle doses
Figure 1 shows the effect of large single doses of
MISO or SR-2508 given 30min before a range of
CY doses, as measured by regrowth delay of the
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Figure 1 The effect on regrowth of the RIF-l tumour
of saline (0, 0) or a large single dose of
3.75mmolkg-1 of MISO (O) or SR-2508 (A, A)
given 30min before a range of CY doses. Data from
two separate experiments are shown. Error bars
represent + 1 s.e.
RIF-1 tumour implanted in the leg. At this dose
both compounds gave a similar large enhancement
of the tumour response to CY. Once again, the
largest dose modification factor was seen at low CY
doses. These results are similar to those obtained
previously with this tumour (Law et al., 1981).
In the bone marrow, both MISO and SR-2508
produced a small enhancement of the cytotoxicity
of CY (100mgkg-1), although in neither case was
the effect significant.
Multiple small injections
To allow a more realistic comparison to be made of
the potential of SR-2508 and MISO as CY chemo-
sensitizers, a series of experiments was carried out
with the RIF-1 tumour (implanted s.c. in the flank)
in which animals received multiple small injections
of the sensitizer to create a "plateau" level in the
plasma, which, at least for MISO, matches the level
in man after a dose which is known to be tolerated
as a single dose (7g oral; Urtasun et al., 1976). The
size of each of the multiple doses was varied over a
wide range, as shown in Table I, from 0.25 times
up to 8 times the dose used in previous multiple
injection experiments (see Brown & Hirst, 1982).
The plasma levels achieved by each of these dose
regimens are shown over an approximately 6h
period for both MISO and SR-2508 in Figure 2
(left panels). At the higher injected doses,
particularly of MISO, blood levels increased
progressively over the 6h period rather than
plateauing. Figure 2 (right panels) shows the mean
plasma level over the 6h period as a function of
administered dose. Plasma levels of SR-2508
increased linearly with increasing injected doses
whereas injected doses of MISO (>x/4) gave pro-
portionately higher blood levels. This result
probably reflects the fact that SR-2508 is largely
eliminated by renal excretion, whereas MISO is
metabolized, a system which can be saturated at
high doses (Workman & Brown, 1981).
The effect of this range of multiple doses of each
drug on the cytotoxicity of CY in the RIF-1 and
SCCVII/St tumours is shown in Figure 3a and b.
Data were obtained using the excision assay
procedure at two dose levels of CY (50 and
100mgkg-1). Although there was some variation in
the effect of CY (experiments were carried out over
a 1 year period) the data within each experiment
show a trend: In general, as the plasma level of
either MISO or SR-2508 was increased, a greater
amount of cell killing was observed in both the
RIF-1 and SCC VII/St tumours. The exception was
when SR-2508 was combined with 50mgkg-1 CY
in the RIF-1 tumour: no enhancement was seen.
A statistical analysis of the tumour data (see
Appendix for details) is summarized in Table III.a
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Figure 2 (a) Blood plasma levels of the two sensitizers during 6h of multiple small injections (0, * =x/4;
* =x/2; A, A=x; X=2x; 0 =4x; V =8x) (see Table I for injection schedule). Error bars (±1 s.e.) are
shown only where they exceed the size of the symbols. Data from 3-7 separate experiments shown. (b) The
mean plasma levels over the injection period plotted as a function of administered dose (see Table I).
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Figure 3 (a-b) The effect of various blood sensitizer concentrations on the response of RIF-1 tumours or
SCC VII/St tumours to two fixed doses of CY. (0 = MISO + 50mg kg- I CY; 0 = SR-2508 + 50mg kg- I CY;
A=MISO+100mgkg-1 CY; A=SR-2508+100mgkg-1 CY). Symbols on the ordinate (4), L) show the
effect of each CY dose combined with multiple saline injections.
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Table Ill Slopes for log survival/log sensitizer concentration ( s.e.)
RIF-I
MISO SR-25-2508
Experiment
number CY(SOmgkg-1) CY(100mgkg-1) CY(SOmgkg-1) CY100mgkg-
1 -0.266+0.265 -0.145+0.304
2 -0.120+0.254 -0.026+0.224
3 -0.405+0.254 +0.182+0.297
4 -0.400+0.254 -1.049+0.224
5 -1.715+0.378 -0.478+0.158
Weighted -0.190+0.184 -0.645+0.162b -0.068+0.180 0.533+0.118b
average (NS) (NS)
slope
Wilcoxon's P<0.05 (NS)
test
SCC VII/St
MISO SR-2508
Experiment
number CY (50mgkg) CY(JOOmgkg-1) CY (50mgkg-1) CY JOOmgkg-1)
6 -0.387+0.254 -0.117+0.227
7 -0.148+0.254 -0.531+0.231
8 -0.316+0.268 +0.182+0.297
9 -0.646+0.266 -0.741 +0.227
10 -0.362+0.396 -0.491+0.148
11 -0.572+0.254 -0.905+0.227
Weighted -0.267+0.180 -0.495+0.142b -0.321 +0.162a 0.780+0.150b
average (NS) (NS)
slope
Wilcoxon's P<0.05 P<0.05
test
NS Not significant, P>0.1.
ao.os<P<o0l.
bP <0.05.
Negative slopes are obtained for the regression lines
when log cell survival is plotted as a function of log
sensitizer concentration in the plasma. These slopes
are significant (P<0.05) when either sensitizer was
combined with the high dose of CY (100mgkg-),
but not significant (P>0.05) at the low dose of CY
(50mgkg- 1).
Figure 4a-c illustrates the effect of sensitizer/CY
combinations in the three normal tissues studied.
Tissue response is plotted against the 6h average
plasma level of sensitizer. When combined with
100mgkg-1 CY neither of the sensitizers affected
the total white blood cell count significantly (Figure
4a). At the lower dose of CY (50 mgkg-1) no
significant enhancement of white cell depression
was seen with any dose although some
enhancement cannot be excluded, especially at the
highest dose of SR-2508. The results obtained for
two separate white cell populations, the lympho-
cytes and neutrophils, (data not shown) were not
different from those of the total. The effects of the
two sensitizers on CY cytotoxicity in the bone
marrow are shown in Figure 4b. At no dose did
either MISO or SR-2508 increase cell killing
significantly in this cell population, however,
because the error bars were large, and the effect of
CY alone was slight, we cannot exclude the
possibility of some enhancing effect by either
compound. For this tissue, only data for CY at a
dose of 100mgkg-1 are shown. At the lower dose
(50mgkg-1) no significant cell killing was obtained
with CY alone or in combination with any dose of
MISO or SR-2508 in this series of experiments.
MISO and SR-2508 enhanced cell killing in theENHANCEMENT OF CY CYTOTOXICITY BY NITROIMIDAZOLES 39
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Figure 4 (a-c) The effect of a wide range of MISO
or SR-2508 concentrations on the response in vivo
of three normal tissues (a, white blood cell counts;
b, bone marrow CFU-S'; c, testis spermatogonia)
to CY. (A=MISO+50mgkg-' CY; A=SR-
2508+50mgkg-l CY; * =MISO+l00mgkg-l CY;
O =SR-2508 + l00mgkg-
I CY; =multiple saline+
50mgkg- I CY; O =multiple saline+ l00 mgkg- I
CY; * =MISO alone; Ol =SR-2508 alone; O = no
treatment control). Results obtained from 2-4 separate
experiments are shown as means + ls.e.
testis when combined with both dose levels of CY
(50 and 100mgkg-1). Enhancement appeared to
increase with the dose of sensitizer and was most
marked at the highest blood level of MISO. It is
possible that the effect of SR-2508 in the testis can
be attributed to the effect of the sensitizer alone
(see Figure 4c) and not to its interaction with CY.
The highest tolerable dose of MISO had no effect
alone, however, and so enhanced cell killing must
represent a real interaction.
Discussion
To be clinically acceptable, a sensitizer of chemo-
therapy or radiation should show high efficiency;
i.e., a relatively low concentration should be
capable of achieving a useful enhancement of
tumour response when it is combined with the
primary agent. The results of these experiments
show that none of the 2-nitroimidazoles in the
series tested was more efficient than MISO at
enhancing the cytotoxicity of CY in the RIF-I and
SCCVII/St tumours, although a less toxic compound
could still be superior for clinical use. While it is
possible that compounds with P values well above
the range tested, or of higher electron-affinity,
could be more efficient, previous experience has
shown such compounds to be rapidly metabolized
or more toxic than MISO (Workman &
Twentyman, 1982b). Also, it seems likely that
compounds with very low P values, which are much
less toxic than MISO, may also be less efficient as
sensitizers of CY cytotoxicity. For example, SR-
2555 (P=0.026) was clearly less efficient under the
conditions of administration used in one of the
experiments (Table II). This is probably a result of
its poor intracellular uptake compared with MISO
and SR-2508 (Brown et al., 1983). However, SR-
2508 with a P value of 0.04, showed a chemosensi-
tizing efficiency similar to that of MISO in several
experiments. SR-2508 is a new drug now in Phase I
clinical trials as a radiosensitizer, so that a
comparison of its chemosensitizing potential with
that of MISO, for which some clinical data will
soon be available, could be valuable. To aid in this
comparison, a statistical analysis of the tumour
data was carried out. In general, at the low dose of
CY (50mgkg-1) it was difficult to establish any
dependence of enhancement by either MISO or SR-
2508 on their plasma concentrations. Although
there was clearly an enhancing effect (except with
SR-2508 in the RIF-1) which was confirmed by
statistical analysis (see Table III and Appendix), it
was difficult to quantify. The data obtained at the
high dose of CY (100mgkg-1) give a much clearer
picture. Both MISO and SR-2508 show significant
dose dependent enhancement of CY cytotoxicity.
Furthermore, the slopes of the regression lines
through the MISO and SR-2508 data (Table III)
are not significantly different from one another nor
is there a significant difference between the two
tumour systems. To simplify our conclusions a
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weighted average slope for all sensitizer treatments
at a CY dose of 100mgkg- was calculated to be
-0.600+0.070 (±s.e.). It is then a simple matter
to determine that a lOx increase in mean plasma
concentration of sensitizer achieves a 4x decrease in
cell survival or that a lOx decrease in cell survival
results from a 46x increase in sensitizer
concentration. The existence of a threshold dose
which must be achieved before measurable
enhancement occurs has been proposed (McNally et
al., 1983) to account for differing results with low
levels of sensitizer from various laboratories. Our
data do not support this. They do not indicate any
dose range over which there was a dramatic change
in enhancement.
An examination of the normal tissue data reveals
a clear relationship between blood sensitizer
concentration and enhancement in the testis but not
in the other assays. The most clinically relevant
indicator of CY cytotoxicity in normal tissue is
probably the white blood cell count. The data at
100mgkg-I of CY are very clear and show no
significant enhancement by either MISO or SR-
2508 so that we can say with some confidence that
a therapeutic gain is indicated when either MISO
or SR-2508 is combined with CY at a relatively
high dose and that the size of the gain should
increase with increasing plasma level of sensitizer.
At 50mgkg-1 of CY the results are much less
clear, particularly with SR-2508 which was
ineffective in the RIF-1 tumour at this CY dose
and yet showed an effect in the SCC VII/St
tumour. This confusing result is made more
problematical by the suggestion of some
enhancement of white cell depletion at the highest
SR-2508 dose combined with 50mgkg-' CY. We
must conclude that we have been unable to
demonstrate a clear therapeutic gain at that dose
level.
To determine what blood levels can be
considered as clinically relevant, the toxicities of the
sensitizers alone must be compared. In the case of
MISO, the blood concentration which can be
tolerated in man is known to be limited to about
100pgml-1 by neurological toxicity so data shown
for higher concentrations are not at present
applicable. When we gave both MISO and SR-2508
as multiple small injections to mice, the dose
administered to reach the LDSO was 3 to 3.5x
higher for SR-2508 than for MISO (data not
shown), but on the basis of mean plasma levels and
so, presumably, tissue exposure of the two
compounds, it was only about 1.5x higher for SR-
2508. Experiments using more clinically relevant
end-points for toxicity show a bigger difference
between the two. Conroy et al. (1982) found SR-
2508 to be about 1/5 as toxic as MISO in mice
using both a rotarod system and an end-point
designed to measure ototoxicity. In lethality studies
with a large animal, the dog, the U.S. National
Cancer Institute pre-clinical study carried out by
Battelle Columbus Laboratories showed SR-2508 to
be approximately 1/6 as toxic as MISO (Brown,
1983). It would seem that the difference in toxicities
is more marked in larger animals and that it is
reasonable to expect that all blood levels shown for
SR-2508 in the present study are clinically
achievable. If this is borne out by clinical
experience there is a good prospect that therapeutic
gains can be obtained with SR-2508. Under some
circumstances it could be superior to MISO, not
because it is a more efficient chemosensitizer but
because it is less toxic and higher blood levels can
be achieved. This conclusion is strikingly different
from that which we reached in a recent study of the
chemosensitization of CCNU (Hirst et al., 1982) in
which SR-2508 was almost totally ineffective when
combined with the nitrosourea. This could well be a
result of the fact that the enhancement of CCNU
cytotoxicity appears to be primarily via alterations
in CCNU pharmacokinetics by MISO (Lee &
Workman, 1983), which would not be expected to
occur with SR-2508.
SR-2508 is likely to enter clinical trials as a
chemosensitizer so we must attempt to interpret our
data in a way which gives some guidance for its
clinical use. There is a clear indication that the
higher the blood level of sensitizer achieved, the
higher will be the therapeutic gain, when
considering the most relevant normal tissue end
point. The dose of CY should also be carefully
considered as this conclusion can only apply to a
relatively high CY dose. More data are needed to
clarify the anomalies at low CY doses.
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Appendix I
Statistical analysis
The tumour data presented in this paper were
subjected to several statistical tests to establish the
relationship between enhancement and sensitizer
concentration. Because the level of cell survival
showed some variability between duplicate
experiments, each experiment was consideredENHANCEMENT OF CY CYTOTOXICITY BY NITROIMIDAZOLES 41
individually for the purpose of determining
variance. Specifically, lines were fitted by least
squares for each experiment and weighted averages
of the slopes were then taken. The s.e. for the
slopes were based on an error variance pooled from
all the lines, having 42 degrees of freedom. This
was permissible because the errors from experiment
to experiment were judged not to be heterogeneous.
The data points for zero dose of sensitizer were not
included in this analysis as there is no realistic way
to include them in a log plot. Slopes for the
individual treatment conditions (e.g.
MISO+100mgkg-1 CY in the RIF-I tumour, for
which there were three separate experiments) were
averaged with weights inversely proportional to
their variances and these averages are shown in
Table III.
Although the slopes of some of the lines for the
same treatment showed considerable variability (see
RIF-1, lOOmgkg-1, Table III) it was considered
legitimate to average them because an overall
negative slope was attested to by the sign test which
showed 9/10 experiments with the RIF-I tumour
had negative slopes giving statistical significance at
the 0.02 level (2 sided) that the sensitizer reduced
survival. A similar analysis of the SCCVII/St data,
where 11/11 slopes were negative, gave a
significance of 0.001 (2 sided). The slopes +2s.e.
were taken as approximating a 95% confidence
interval. In comparing any 2 slopes b1 and b2 s.e.
of the difference was calculated from the following
expression:
s.e. (b, -b2) = /se2(b1)+se2(b2)
On this basis all the averaged slopes at
100mgkg-' (Table III) are significantly different
from zero, while at 50mgkg- none are
significantly different from zero. It can be
appreciated from the data at 50mgkg-t in Figure
3, however, that in all cases except when SR-2508
was used in the RIF-1 tumour the sensitizer
data fall below the controls on the ordinate
(50mgkg-1 CY+saline). Wilcoxon's test
(Armitage, 1971) allows us to determine the
probability of this occurring by chance for each set
of experimental conditions (see Table III). All the P
values are less than 0.05 except, as we might expect,
for the SR-2508 data in the RIF-1 tumour.
Therefore, with the exception of this one case, we
can say that combined with 50mgkg-1 CY each
sensitizer enhances cytotoxicity significantly, but
that the dependence on sensitizer concentration is
unclear.
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